Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E.
Other stock markets
 01:59:08 2024-06-04 pm EDT 		5-day change 1st Jan Change
3.77 CAD +1.34% Intraday chart for HLS Therapeutics Inc. +0.27% -4.56%
May. 28 HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study MT
May. 28 HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
HLS Therapeutics Inc. announces an Equity Buyback for 1,607,892 shares, representing 5% of its issued share capital.
HLS Therapeutics Reports Q3 2023 Revenue of US$16.0 Million, Renews Normal Course Issuer Bid
HLS Therapeutics Inc. authorizes a Buyback Plan.
HLS Therapeutics Q2 Net Loss; Revenue was US$16.4 Million, Vascepa Net Revenue up 49% YoY
HLS Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
HLS Therapeutics Inc. Announces Board Changes
HLS Therapeutics Inc. Elects Christian Roy as Director
HLS Therapeutics Up 3% As Announces Retirement Of 2 Board Directors, Strikes Agreement with Polar Asset Management Partners
Hls Therapeutics Inc. Announces Resignation of Director
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLS Stock
  4. News HLS Therapeutics Inc.
  5. Other languages